Increasing rates of obesity and diabetes have driven corresponding increases in related cardiorenal and metabolic diseases. In many patients, these conditions occur together, further increasing morbidity and mortality risks to the individual. Yet all too often, the risk factors for these disorders are not addressed promptly in clinical practice, leading to irreversible pathologic progression. To address this gap, we convened a Task Force of experts in cardiology, nephrology, endocrinology, and primary care to develop recommendations for early identification and intervention in obesity, diabetes, and other cardiorenal and metabolic diseases. The recommendations include screening and diagnosis, early interventions with lifestyle, and when and how to implement medical therapies. These recommendations are organized into primary and secondary prevention along the continuum from obesity through the metabolic syndrome, prediabetes, diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), atherosclerotic cardiovascular disease (ASCVD) and atrial fibrillation, chronic kidney disease (CKD), and heart failure (HF). The goal of early and intensive intervention is primary prevention of comorbidities or secondary prevention to decrease further worsening of disease and reduce morbidity and mortality. These efforts will reduce clinical inertia and may improve patients' well-being and adherence.

Advanced Internal Medicine Group PC East Hills NY USA

AdventHealth Translational Research Institute Orlando FL USA

Ahmanson UCLA Cardiomyopathy Center Ronald Reagan UCLA Medical Center UCLA Preventative Cardiology Program UCLA Division of Cardiology David Geffen School of Medicine at UCLA Los Angeles CA USA

American Heart Association Comprehensive Hypertension Center University of Chicago Pritzker School of Medicine Chicago IL USA

Baylor Scott and White Research Institute Baylor Scott and White Health Dallas TX USA

Cardiology Division Harvard Medical School Massachusetts General Hospital Cardiometabolic Trials Baim Institute Boston MA USA

Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Medicine Donald and Barbara Zucker School of Medicine at Hofstra Northwell Hempstead NY USA

Department of Medicine Duke University Medical Center Durham NC USA

Division of Cardiology Johns Hopkins University School of Medicine Baltimore MD USA

Division of Endocrinology and Duke Clinical Research Institute Duke University Medical Center Durham NC USA

Division of Nephrology Department of Medicine University of Maryland School of Medicine Baltimore MD USA

Grunberger Diabetes Institute Internal Medicine and Molecular Medicine and Genetics Wayne State University School of Medicine Department of Internal Medicine Oakland University William Beaumont School of Medicine Bloomfield Hills MI USA

Metabolic Institute of America Tarzana CA USA

Sansum Diabetes Research Institute Santa Barbara CA USA

Section of Endocrinology Tulane University Health Sciences Center New Orleans LA USA

University of California Medical Center Kushner Wellness Center Long Beach CA USA

University of Mississippi Medical Center Jackson MS USA

University of Texas Health Science Center at San Antonio Texas Diabetes Institute San Antonio TX USA

University of Texas Southwestern Medical Center and Parkland Health and Hospital System Dallas TX USA

Washington University School of Medicine Saint Louis MO USA

000      

00000naa a2200000 a 4500

001      

bmc23004303

003      

CZ-PrNML

005      

20230425141256.0

007      

ta

008      

230418s2023 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.jdiacomp.2022.108389 $2 doi

035    __

$a (PubMed)36669322

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Handelsman, Yehuda $u Metabolic Institute of America, Tarzana, CA, USA. Electronic address: yhandelsman@gmail.com

245    10

$a Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases / $c Y. Handelsman, J. Butler, GL. Bakris, RA. DeFronzo, GC. Fonarow, JB. Green, G. Grunberger, JL. Januzzi, S. Klein, PR. Kushner, DK. McGuire, ED. Michos, J. Morales, RE. Pratley, MR. Weir, E. Wright, VA. Fonseca

520    9_

$a Increasing rates of obesity and diabetes have driven corresponding increases in related cardiorenal and metabolic diseases. In many patients, these conditions occur together, further increasing morbidity and mortality risks to the individual. Yet all too often, the risk factors for these disorders are not addressed promptly in clinical practice, leading to irreversible pathologic progression. To address this gap, we convened a Task Force of experts in cardiology, nephrology, endocrinology, and primary care to develop recommendations for early identification and intervention in obesity, diabetes, and other cardiorenal and metabolic diseases. The recommendations include screening and diagnosis, early interventions with lifestyle, and when and how to implement medical therapies. These recommendations are organized into primary and secondary prevention along the continuum from obesity through the metabolic syndrome, prediabetes, diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), atherosclerotic cardiovascular disease (ASCVD) and atrial fibrillation, chronic kidney disease (CKD), and heart failure (HF). The goal of early and intensive intervention is primary prevention of comorbidities or secondary prevention to decrease further worsening of disease and reduce morbidity and mortality. These efforts will reduce clinical inertia and may improve patients' well-being and adherence.

650    _2

$a lidé $7 D006801

650    12

$a diabetes mellitus $7 D003920

650    _2

$a rizikové faktory $7 D012307

650    _2

$a komorbidita $7 D015897

650    12

$a hypertenze $7 D006973

650    _2

$a obezita $x terapie $7 D009765

650    12

$a kardiovaskulární nemoci $x komplikace $x epidemiologie $x prevence a kontrola $7 D002318

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

700    1_

$a Butler, Javed $u Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX, USA; University of Mississippi Medical Center, Jackson, MS, USA

700    1_

$a Bakris, George L $u American Heart Association Comprehensive Hypertension Center, University of Chicago Pritzker School of Medicine, Chicago, IL, USA

700    1_

$a DeFronzo, Ralph A $u University of Texas Health Science Center at San Antonio, Texas Diabetes Institute, San Antonio, TX, USA

700    1_

$a Fonarow, Gregg C $u Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center, UCLA Preventative Cardiology Program, UCLA Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

700    1_

$a Green, Jennifer B $u Division of Endocrinology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA

700    1_

$a Grunberger, George $u Grunberger Diabetes Institute, Internal Medicine and Molecular Medicine & Genetics, Wayne State University School of Medicine, Department of Internal Medicine, Oakland University William Beaumont School of Medicine, Bloomfield Hills, MI, USA; Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Januzzi, James L $u Cardiology Division, Harvard Medical School, Massachusetts General Hospital, Cardiometabolic Trials, Baim Institute, Boston, MA, USA

700    1_

$a Klein, Samuel $u Washington University School of Medicine, Saint Louis, MO, USA; Sansum Diabetes Research Institute, Santa Barbara, CA, USA

700    1_

$a Kushner, Pamela R $u University of California Medical Center, Kushner Wellness Center, Long Beach, CA, USA

700    1_

$a McGuire, Darren K $u University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, TX, USA

700    1_

$a Michos, Erin D $u Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

700    1_

$a Morales, Javier $u Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; Advanced Internal Medicine Group, PC, East Hills, NY, USA

700    1_

$a Pratley, Richard E $u AdventHealth Translational Research Institute, Orlando, FL, USA

700    1_

$a Weir, Matthew R $u Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

700    1_

$a Wright, Eugene $u Department of Medicine, Duke University Medical Center, Durham, NC, USA

700    1_

$a Fonseca, Vivian A $u Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, LA, USA

773    0_

$w MED00002638 $t Journal of diabetes and its complications $x 1873-460X $g Roč. 37, č. 2 (2023), s. 108389

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36669322 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230418 $b ABA008

991    __

$a 20230425141252 $b ABA008

999    __

$a ok $b bmc $g 1924776 $s 1190512

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 37 $c 2 $d 108389 $e 20230103 $i 1873-460X $m Journal of diabetes and its complications $n J. Diabetes Complicat. $x MED00002638

LZP    __

$a Pubmed-20230418